Improving the use of a new imaging agent to predict cancer treatment response
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution
This study is looking at a special imaging tool that helps doctors see how well certain cancer treatments are working, so they can better understand which patients will benefit from these treatments and which ones might not, ultimately aiming to make cancer care more personalized and effective for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trevarx Biomedical, INC. NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10930956 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of a PET imaging agent called [18F]Fluorthanatrace ([18F]FTT), which helps visualize how well certain cancer treatments, specifically PARP inhibitors, are working in patients. By using this imaging agent, the study aims to identify patients who are likely to benefit from these treatments and those who may not respond. The approach involves conducting clinical trials to correlate the imaging results with tumor samples, ensuring that the imaging can accurately predict treatment outcomes. This could lead to more personalized and effective cancer therapies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast, ovarian, or prostate cancers who are being considered for PARP inhibitor therapies.
Not a fit: Patients who do not have the specific gene mutations targeted by PARP inhibitors or those not eligible for PARP therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a reliable method for predicting which cancer patients will respond to specific treatments, potentially improving treatment outcomes.
How similar studies have performed: Previous studies have shown promising results with similar imaging approaches, indicating a strong potential for success in this novel application.
Where this research is happening
Philadelphia, United States
- Trevarx Biomedical, INC. — Philadelphia, United States (Active)
Researchers
- Principal investigator: Mikhail, Michel — Trevarx Biomedical, INC.
- Study coordinator: Mikhail, Michel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.